Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANZadapt: Adaptive vs Continuous Abiraterone or Enzalutamide in mCRPC
NCT05393791Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2022
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of abiraterone, enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Leiden University Medical Center. Started Nov 2022; status: recruiting.
02
Drugs
abirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05393791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393791.